Literature DB >> 31776603

Percutaneous transhepatic biliary drainage in patients at higher risk for adverse events: experience from a tertiary care referral center.

Pankaj Gupta1,2, Muniraju Maralakunte3, Seema Rathee3, Jayanta Samanta4, Vishal Sharma4, Harshal Mandavdhare4, Saroj K Sinha4, Usha Dutta4, Rakesh Kochhar4.   

Abstract

BACKGROUND: Despite advances in endoscopic drainage procedures, percutaneous transhepatic biliary drainage (PTBD) remains an essential interventional radiology (IR) procedure. Several factors may adversely affect the success of PTBD. We report the experience of our IR unit with PTBD in patients considered at higher risk for adverse events. MATERIAL: Consecutive PTBDs performed between November 2017 and April 2019 were retrospectively reviewed. The patients at increased risk for adverse events from PTBD, defined by one or more of the following factors: non-dilated system, moderate amount of perihepatic fluid, coagulopathy, altered sensorium, and PTBD performed at bedside, were identified. Technical success, complications, and outcome at 3 months were recorded.
RESULTS: During the study period, PTBDs were performed in 90 patients. PTBDs in 57 (63.3%) patients (mean age 47.6 years, 35 females) were identified as predisposing to higher risk for adverse events. Left and right PTBD were performed in 37 (64.9%) and 15 (26.3%) patients, respectively. Bilateral PTBDs were performed in three (5.2%) patients. In two (3.5%) cases, biliary access was obtained via percutaneous cholecystostomy. Overall technical success of 91.2% (n = 52) was achieved. Carcinoma gallbladder was the most common underlying cause. Non-dilated ductal system was the most common condition deemed to predispose to higher risk for adverse events (n = 32, 56.1%), followed by perihepatic fluid (n = 9, 15.8%), and deranged coagulation parameters (n = 9, 15.8%). PTBD was performed at bedside in intensive care unit in 5 (8.8%) patients. Two (3.5%) patients had altered sensorium. Major complications in the form of biliary peritonitis were observed in three (5.2%) patients. No procedure-related mortality was observed.
CONCLUSION: PTBD can be effectively and safely performed even in situations deemed to predispose patients to increased risk for adverse events. Thus, the mere presence of these conditions should not cause a denial of PTBD.

Entities:  

Keywords:  Biliary drainage; Biliary obstruction; PTBD; Percutaneous drainage

Mesh:

Year:  2020        PMID: 31776603     DOI: 10.1007/s00261-019-02344-1

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  5 in total

1.  Role of Percutaneous Transhepatic Biliary Drainage as an Adjunct to Endoscopic Retrograde Cholangiopancreatography.

Authors:  Nikita Verma; Hema H K; Pankaj Gupta; Mandeep Kang; Naveen Kalra; Jayanta Samanta; Harshal Mandavdhare; Vishal Sharma; Usha Dutta; Rakesh Kochhar; Manavjit S Sandhu
Journal:  J Clin Exp Hepatol       Date:  2021-09-10

2.  Side-by-side versus stent-in-stent bilateral stenting for malignant hilar biliary obstruction: a meta-analysis.

Authors:  Liang Chen; Guo-Ming Gao; Dong-Lu Li; Zhong-Ke Chen
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-01-09       Impact factor: 1.627

3.  Should patients with unresectable gallbladder cancer with hilar involvement undergo unilateral or bilateral percutaneous biliary drainage in the setting of cholangitis?

Authors:  Pankaj Gupta; Varun Bansal; Naveen Kalra; Jayanta Samanta; Harshal Mandavdhare; Vishal Sharma; Usha Dutta; Rakesh Kochhar; Manavjit Singh Sandhu
Journal:  Clin Exp Hepatol       Date:  2021-03-25

4.  Covered vs bare stent for distal malignant biliary obstruction due to primary common biliary cancer.

Authors:  Ling Tang; Kai-Hu Bao; Yuan-Shun Xu; Peng-Hui Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-22       Impact factor: 1.889

Review 5.  Endoscopic or percutaneous biliary drainage in hilar cholangiocarcinoma: When and how?

Authors:  Tudor Mocan; Adelina Horhat; Emil Mois; Florin Graur; Cristian Tefas; Rares Craciun; Iuliana Nenu; Mihaela Spârchez; Zeno Sparchez
Journal:  World J Gastrointest Oncol       Date:  2021-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.